RESEARCH MONOGRAPH · KDC-MN-213

Levomilnacipran

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

Pure-SNRI single enantiomer that should have done better than it did. Cleanest NET-favored SNRI available

Levomilnacipran is the (1S,2R)-enantiomer of milnacipran, brought to market by Forest Labs in 2013 as Fetzima with the reasonable argument that the single enantiomer offered a more favorable SERT:NET binding ratio than the racemic parent (closer to 1:2 NET-favored vs the racemate's roughly balanced profile). Whether that actually justified a separate drug application is the standard chiral-switch debate, but the pharmacology is genuinely useful as a research tool.

The receptor profile is what makes levomilnacipran interesting: it's the most NET-favored SNRI in clinical use, which makes it pharmacologically distinct from venlafaxine and duloxetine (both SERT-favored) and from racemic milnacipran (roughly balanced). For research questions about noradrenergic vs serotonergic contributions to antidepressant action, fatigue, attention, or motivation, levomilnacipran is the cleanest tool compound in the SNRI class.

Half-life is around 12 hours, primarily renally cleared, which means CYP-mediated drug interactions are minimal. That's a real practical advantage over duloxetine (1A2 / 2D6) and venlafaxine (2D6) for polypharmacy populations. The extended-release formulation provides reasonable once-daily dosing kinetics.

Clinical efficacy is reasonable but unremarkable. The MDD trials showed response and remission rates roughly equivalent to other SNRIs, with maybe a small advantage in functional outcomes (the relatively NE-favored profile theoretically targets motivation and energy more than the SERT-dominant SNRIs, though the trial endpoints to actually test this hypothesis are imperfect). The Cipriani-style meta-analytic position is mid-pack, partly because the trial base is smaller than for the older SNRIs.

What we don't like: tachycardia and blood pressure elevation are more pronounced than for the SERT-favored SNRIs, which fits the NET-dominant pharmacology. Urinary hesitancy from alpha-adrenergic effects is real. The cost during the patent years was substantial and limited clinical adoption, though generic availability in the US since 2023 has improved that calculus.

Sourcing is workable but less straightforward than for the older SNRIs because reference standards are less commonly stocked. For research applications focused on NET-dominant SNRI pharmacology levomilnacipran is the obvious choice, and we think it's genuinely underused as a tool compound in noradrenergic-mechanism research. Cleanest pure SNRI available for that purpose.

Evidence: 70
Mechanism: 85
Reliability: 72
Safety: 75
Sourcing: 72
Value: 65
Signal: 55
Staying power: 60

Plain-language summary Intrigue 54 / 100

Levomilnacipran (Fetzima) is one mirror-image half of milnacipran, sold separately by Forest Pharmaceuticals in the US after FDA approval in 2013. It is unusual among SNRIs because it preferentially blocks the norepinephrine pump rather than the serotonin one, which is the opposite of duloxetine and venlafaxine. That noradrenergic emphasis was meant to deliver stronger effects on energy, motivation, and concentration in depressed patients. Trial data are favorable but not overwhelming, and the drug never gained the prescribing momentum of duloxetine. The parent compound milnacipran (the racemic mix) is widely used in Europe and Japan for depression and is approved in the US specifically for fibromyalgia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Pure SNRI ((1S,2R)-enantiomer)

The (1S,2R)-enantiomer of milnacipran; a pure SNRI with strong NET selectivity over SERT and minimal off-target activity.

Abstract

Levomilnacipran ((1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; CAS 96847-55-1 (HCl salt); molecular formula C15H22N2O; molecular weight 246.35) is the (1S,2R)-enantiomer of milnacipran, marketed as Fetzima by Forest Pharmaceuticals after FDA approval in 2013. Distinct among SNRIs for inverse selectivity: NET affinity (Ki approximately 11 nM) exceeds SERT affinity (Ki approximately 19 nM) by approximately 2-fold, the opposite of duloxetine and venlafaxine. The compound has minimal off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic sites. Plasma half-life is approximately 12 hours; metabolism is primarily renal (excreted unchanged) with minor CYP3A4 contribution, producing minimal drug-drug interaction potential. Approved for major depressive disorder; off-label investigation in attention deficit and chronic pain conditions. The dosing form is extended-release. Used as the reference NET-selective SNRI in mechanism studies.

Mechanism of action

NET-selective SNRI (NET preferred over SERT, opposite of typical SNRIs). Minimal off-target receptor activity.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Auclair AL, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013.
Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder. Drug Des Devel Ther 2015.
Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci 2014.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-213

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Levomilnacipran

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs